<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2565-005X</journal-id>
<journal-title><![CDATA[Gaceta mexicana de oncología]]></journal-title>
<abbrev-journal-title><![CDATA[Gac. mex. oncol.]]></abbrev-journal-title>
<issn>2565-005X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Oncología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2565-005X2020000300090</article-id>
<article-id pub-id-type="doi">10.24875/j.gamo.19000323</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Experiencia en el diagnóstico histopatológico de tumores astrocíticos en el Hospital Infantil Teletón de Oncología]]></article-title>
<article-title xml:lang="en"><![CDATA[Experience in histopathological diagnosis of astrocytic tumors at Hospital Infantil Teletón de Oncología]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Angeles-Romero]]></surname>
<given-names><![CDATA[Atzin A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Peralta-Velázquez]]></surname>
<given-names><![CDATA[Vanesa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Escamilla-Asain]]></surname>
<given-names><![CDATA[Gabriela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguilar-Escobar]]></surname>
<given-names><![CDATA[Virginia D.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vega-Vega]]></surname>
<given-names><![CDATA[María Lourdes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Esmer-Sanch]]></surname>
<given-names><![CDATA[María del Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Infantil Teletón de Oncología Querétaro Laboratorio de Patología ]]></institution>
<addr-line><![CDATA[ Qro.]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Infantil Teletón de Oncología Querétaro Dirección médica ]]></institution>
<addr-line><![CDATA[ Qro.]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Infantil Teletón de Oncología Querétaro Subdirección de Diagnóstico y Banco de sangre ]]></institution>
<addr-line><![CDATA[ Qro.]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Infantil Teletón de Oncología Querétaro Subdirección de Enseñanza ]]></institution>
<addr-line><![CDATA[ Qro.]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2020</year>
</pub-date>
<volume>19</volume>
<numero>3</numero>
<fpage>90</fpage>
<lpage>98</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2565-005X2020000300090&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2565-005X2020000300090&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2565-005X2020000300090&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Los tumores de sistema nervioso central ocupan el segundo lugar en frecuencia en pediatría. La clasificación de la Organización Mundial de la Salud de 2016 incorporó características moleculares para tipificar la mayoría de los tumores. En el presente trabajo se describen los hallazgos histopatológicos con la aplicación del marcador de la isocitrato deshidrogenasa 1 (IDH-1) en el análisis de los tumores astrocíticos según lo recomienda esta nueva clasificación.  Material y métodos: Se realizó un estudio retrospectivo, transversal, observacional y descriptivo usando el archivo de laminillas de tumores astrocíticos del Hospital Infantil Teletón de Oncología, teñidas con hematoxilina y eosina, inmunohistoquímica y expresión de IDH-1 para clasificarlos de acuerdo con la clasificación de la OMS de 2016.  Resultados: Se incluyeron 21 casos, de los cuales el 52.3% correspondieron a astrocitomas de bajo grado, el 23.8% a astrocitomas de alto grado y el 23.8% no se analizaron; la localización supratentorial (n = 12) fue la más observada. Todos los tumores gliales infiltrantes (n = 8), cuatro clasificados como grado II, uno grado III y tres grado IV mostraron expresión de la IDH-1.  Discusión: La clasificación de la OMS de 2016 incorpora entre otros marcadores la IDH-1 al análisis de los tumores gliales, siendo este un marcador que pudiera predecir respuesta a la temozolamida y mejor pronóstico. El diagnóstico preciso de las neoplasias del sistema nervioso central SNC debe fundamentarse en el análisis histopatológico; se espera que en el futuro se defina con mayor precisión la utilidad de incorporar técnicas moleculares en el diagnóstico, estadificación, respuesta a terapias blanco y en el pronóstico, permitiendo a los patólogos incorporar los avances biotecnológicos priorizando costo y aplicabilidad clínica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Tumors of the central nervous system occupies the second place in frequency among Childhood malignancies. The World Health Organization actualized its classification on 2016 incorporating molecular tests added to the classic histologic and immunohistochemical findings. We describe the histopathological findings in addition to the expression of the enzyme isocitrate dehydrogenase 1 (IDH-1) in the analysis of the astrocytic tumors as this new classification recommended.  Material and methods: A retrospective, transversal, observational and descriptive study was carried out over the tumoral slides samples of cases attended at the Teleton Oncology Children&#8217;s Hospital, the slides were dyed with hematoxylin/eosin, and immunohistochemistry and expression of IDH-1 were used to classify them according to the WHO 2016.  Results: Twenty-one consecutive cases with astrocytic tumors were included; 53.8% classified as low grade, 23.8% as high-grade and 23.8% were not analyzed; the supratentorial location (n = 12) was the most observed. Eight infiltrating glial tumors, four corresponding to grade II, one grade III and three IV were selected to perform IDH-1 all showing expression of mutated HDI-1.  Discussion: The WHO 2016 classification incorporates, among other markers, IDH-1 to the analysis of glial tumors being the only that could predict response to temozolamide and better prognosis. The accurate diagnosis of CNS neoplasms should be based on the clinical, imaging and histopathological diagnosis to know more precisely the prognosis of the patient. In the future, it is expected that molecular techniques will be useful in diagnosing, staging and response to treatment with targeted therapies, and in the prognosis of cancer. The pathologists will have to incorporate the biotechnological advances prioritizing the cost and the clinical applicability of them.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Tumores gliales]]></kwd>
<kwd lng="es"><![CDATA[Clasificación OMS 2016]]></kwd>
<kwd lng="es"><![CDATA[Tumores de sistema nervioso central]]></kwd>
<kwd lng="es"><![CDATA[Astrocitos]]></kwd>
<kwd lng="en"><![CDATA[Glial tumours]]></kwd>
<kwd lng="en"><![CDATA[Classification WHO 2016]]></kwd>
<kwd lng="en"><![CDATA[Central nervous system tumors]]></kwd>
<kwd lng="en"><![CDATA[Astrocytes]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sinning]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clasificación de los tumores cerebrales]]></article-title>
<source><![CDATA[Rev Med Clin Condes]]></source>
<year>2017</year>
<volume>28</volume>
<page-range>339-42</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Louis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ohgaki]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wiestler Cavenee]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
<name>
<surname><![CDATA[Burger]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Jouvet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Who classification of tumours of the central nervous system]]></article-title>
<source><![CDATA[Acta Neuropathol]]></source>
<year>2007</year>
<volume>114</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>97-109</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Las Heras]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuropatología:diagnóstico con biología molecular]]></article-title>
<source><![CDATA[Rev Med Clin Condes]]></source>
<year>2017</year>
<volume>28</volume>
<page-range>352-59</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Louis]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[Perry]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Reifenberger]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[von Deimling]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Figarella-Branger]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cavenee]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 2016 World Health Organization Classification of Tumors of the Central Nervous System:a summary]]></article-title>
<source><![CDATA[Acta Neuropathol]]></source>
<year>2016</year>
<volume>131</volume>
<page-range>803-20</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Concha]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Manejo de los tumores cerebrales astrocíticos y oligodendrogliales]]></article-title>
<source><![CDATA[Rev Med Clin Condes]]></source>
<year>2017</year>
<volume>28</volume>
<page-range>392-400</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valenzuela]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nuevas terapias en el manejo de los gliomas de alto grado]]></article-title>
<source><![CDATA[Rev Med Clin Condes]]></source>
<year>2017</year>
<volume>28</volume>
<page-range>401-6</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alegría-Loyola]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumores del sistema nervioso central]]></article-title>
<source><![CDATA[Rev Med Inst Mex Seguro Soc]]></source>
<year>2017</year>
<volume>55</volume>
<page-range>330-40</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wrensch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Minn]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Chew]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bondy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of primary brain tumors:Current concepts and review of the literature]]></article-title>
<source><![CDATA[Neuro Oncol]]></source>
<year>2002</year>
<volume>4</volume>
<page-range>278-99</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verhaak]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Hoadley]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Purdom]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Qi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wilkerson]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH-1, EGFR and NF1]]></article-title>
<source><![CDATA[Cancer Cell]]></source>
<year>2010</year>
<volume>17</volume>
<page-range>98-110</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>CBTRUS Fact sheet 2016</collab>
<source><![CDATA[Central Brain Tumor Registry of the United States (CBTRUS)]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ostrom]]></surname>
<given-names><![CDATA[QT]]></given-names>
</name>
<name>
<surname><![CDATA[Gittleman]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[de Blank]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Finlay]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Gurney]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[McKean-Cowdin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[American Brain Tumor Association Adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008-2012]]></article-title>
<source><![CDATA[Neuro Oncol]]></source>
<year>2016</year>
<volume>18</volume>
<page-range>1-50</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ostrom]]></surname>
<given-names><![CDATA[QT]]></given-names>
</name>
<name>
<surname><![CDATA[Gittleman]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Fulop]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Blanda]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kromer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CBTRUS Statistical Report:Primary brain and central nervous system tumors diagnosed in the United States in 2008-2012]]></article-title>
<source><![CDATA[Neuro Oncol]]></source>
<year>2015</year>
<volume>17</volume>
<page-range>4-62</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verhaak]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Hoadley]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Purdom]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Qi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wilkerson]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH-1, EGFR, and NF1]]></article-title>
<source><![CDATA[Cancer Cell]]></source>
<year>2010</year>
<volume>19</volume>
<page-range>98-110</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Broniscer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chamdine]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Hwang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Pounds]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Onar-Thomas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas]]></article-title>
<source><![CDATA[Acta Neuropathol]]></source>
<year>2016</year>
<volume>131</volume>
<page-range>299-307</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brat]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Verhaak]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Aldape]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Yung]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
<name>
<surname><![CDATA[Salama]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<collab>Cancer Genome Atlas Research Network</collab>
<article-title xml:lang=""><![CDATA[Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>372</volume>
<page-range>2481-98</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huse]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Diamond]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenblum]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma:a true &#8220;oligoastrocytoma&#8221;?]]></article-title>
<source><![CDATA[Acta Neuropathol]]></source>
<year>2015</year>
<volume>129</volume>
<page-range>151-53</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joseph]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Phillips]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dahiya]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Felicella]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tihan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Brat]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic implications of IDH-1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants]]></article-title>
<source><![CDATA[Mod Pathol]]></source>
<year>2013</year>
<volume>26</volume>
<page-range>315-26</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osborn]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osborn´s Brain]]></article-title>
<source><![CDATA[Imaging pathology and anatomy]]></source>
<year>2018</year>
<edition>2nd ed</edition>
<page-range>509-52</page-range><publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
